NCT03709082
Breast Cancer Type: HER2+
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express both HER2+ & ER+; Patients must have prior treatment with a taxane & trastuzumab
Exclusions: Patients with leptomeningeal disease; Patients with prior therapy of a CDK 4/6 inhibitor
https://ClinicalTrials.gov/show/NCT03709082